CY1110716T1 - Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας - Google Patents

Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας

Info

Publication number
CY1110716T1
CY1110716T1 CY20101100718T CY101100718T CY1110716T1 CY 1110716 T1 CY1110716 T1 CY 1110716T1 CY 20101100718 T CY20101100718 T CY 20101100718T CY 101100718 T CY101100718 T CY 101100718T CY 1110716 T1 CY1110716 T1 CY 1110716T1
Authority
CY
Cyprus
Prior art keywords
viruses
cells
multiplication
implication
volume
Prior art date
Application number
CY20101100718T
Other languages
English (en)
Inventor
Jürgen VORLOP
Christian Frech
Holger LÜBBEN
Jens-Peter Gregersen
Original Assignee
Novartis Vaccines And Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics Gmbh filed Critical Novartis Vaccines And Diagnostics Gmbh
Publication of CY1110716T1 publication Critical patent/CY1110716T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Η εφεύρεση αναφέρεται σε μεθόδους για τον πολλαπλασιασμό ιών εντός κυτταροκαλλιέργειας, στις οποίες κύτταρα μολύνονται με ιό και μετά τη μόλυνση τα κύτταρα καλλιεργούνται εντός κυτταροκαλλιέργειας κάτω από συνθήκες που καθιστούν δυνατό τον πολλαπλασιασμό των ιών και ταυτοχρόνως το στοχευμένο, περαιτέρω, τουλάχιστον 2πλάσιο πολλαπλασιασμό των κυττάρων. Η εφεύρεση αναφέρεται περαιτέρω στη χρήση των λαμβανόμενων ιών ή των πρωτεϊνών που παράγονται από αυτούς για την παραγωγή φαρμακευτικών και διαγνωστικών μέσων.
CY20101100718T 2001-09-12 2010-07-30 Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας CY1110716T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
EP02777068A EP1427817B1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Publications (1)

Publication Number Publication Date
CY1110716T1 true CY1110716T1 (el) 2015-06-10

Family

ID=7698761

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100718T CY1110716T1 (el) 2001-09-12 2010-07-30 Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας

Country Status (17)

Country Link
US (1) US20050118698A1 (el)
EP (1) EP1427817B1 (el)
JP (2) JP2005502357A (el)
KR (1) KR100968141B1 (el)
AT (1) ATE466932T1 (el)
AU (1) AU2002338666B2 (el)
BR (1) BR0212469A (el)
CA (1) CA2456561A1 (el)
CY (1) CY1110716T1 (el)
DE (2) DE10144903A1 (el)
DK (1) DK1427817T3 (el)
ES (1) ES2345606T3 (el)
HK (1) HK1062029A1 (el)
NZ (1) NZ532203A (el)
PT (1) PT1427817E (el)
SI (1) SI1427817T1 (el)
WO (1) WO2003023025A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094915A (zh) * 2004-05-20 2007-12-26 益得生物医学公司 生产流感疫苗的方法
DE602005024827D1 (de) 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2663196A1 (en) * 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
WO2008105931A2 (en) 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN102215865B (zh) 2008-09-24 2013-10-30 米迪缪尼有限公司 病毒纯化方法
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
US20110217330A1 (en) 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
AU2010309404B2 (en) * 2009-10-20 2015-07-09 Seqirus UK Limited Improved reverse genetics methods for virus rescue
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
BR112012028146A2 (pt) 2010-05-06 2015-09-15 Novartis Ag compostos de peróxido orgânico para inativação de microorganismos
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
AU2011290471B2 (en) 2010-08-20 2015-08-20 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
DK2675476T3 (en) * 2011-02-17 2015-12-14 Boehringer Ingelheim Vetmed Process for producing PRRSV on a commercial scale
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
US20150210986A1 (en) * 2012-08-24 2015-07-30 Ge Healthcare Bio-Sciences Corp. Virus purification and formulation process
KR101370512B1 (ko) 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
HUE051783T2 (hu) 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
CN108239619A (zh) * 2016-12-23 2018-07-03 甘肃健顺生物科技有限公司 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术
CN108570444A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 St细胞驯化悬浮方法和二阶病毒生产工艺
CN108570445A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Pk15细胞驯化悬浮方法和二阶病毒生产工艺
CN108570454A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Mdbk驯化悬浮方法和二阶病毒生产工艺
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6110724A (en) * 1996-10-18 2000-08-29 The Research Foundation For Microbial Diseases Of Osaka University Rotavirus antigen, vaccine and diagnostic agent for rotavirus infections, and a method for producing the antigen
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
DE60142506D1 (de) * 2000-03-03 2010-08-19 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle

Also Published As

Publication number Publication date
KR100968141B1 (ko) 2010-07-06
SI1427817T1 (sl) 2010-08-31
DE10144903A1 (de) 2003-03-27
WO2003023025A1 (de) 2003-03-20
EP1427817B1 (de) 2010-05-05
HK1062029A1 (en) 2004-10-15
AU2002338666B2 (en) 2008-11-20
BR0212469A (pt) 2004-08-24
KR20050027164A (ko) 2005-03-17
EP1427817A1 (de) 2004-06-16
ES2345606T3 (es) 2010-09-28
DE50214416D1 (de) 2010-06-17
JP2005502357A (ja) 2005-01-27
NZ532203A (en) 2005-04-29
ATE466932T1 (de) 2010-05-15
JP2010246559A (ja) 2010-11-04
US20050118698A1 (en) 2005-06-02
PT1427817E (pt) 2010-08-10
CA2456561A1 (en) 2003-03-20
DK1427817T3 (da) 2010-08-23

Similar Documents

Publication Publication Date Title
CY1110716T1 (el) Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
WO2003023021A3 (de) Verfahren zur herstellung eines aktiven bestandteils eines arznei- oder diagnosemittels in mdck-zell-suspensionskultur
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
WO2003091401A3 (en) Multi plasmid system for the production of influenza virus
BR9610550A (pt) Método para a produção de uma vacina viral para um vírus animal método para determinar a atividade de um composto contra um vírus animal e método para detectar a presença de um vírus em uma amostra
DK0891420T3 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
DE60037450D1 (de) Funf-helix protein
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
WO2020198509A3 (en) Modified oligonucleotides with increased stability
WO2006029029A3 (en) Compositions for detection of latent hiv reactivation and methods of using the same
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
EP2327722A3 (en) Mammalian genes involved in viral infection and tumor suppression
WO2004071430A3 (en) RNAi TARGETING OF VIRUSES
WO2005092924A8 (en) Rab9a, rab11a, and modulators thereof related to infectious disease
DE60132443D1 (de) In lebenden zielzellen
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
WO2007002172A3 (en) Hiv-1 protease inhibitors
ATE511397T1 (de) Lungenzellen von baumwollratten zur virenkultur
EP1546415A4 (en) ANTI-TSG101 ANTIBODIES AND USES THEREOF FOR TREATING VIRAL INFECTIONS
EA200101228A1 (ru) ИСПОЛЬЗОВАНИЕ АНТИТЕЛ, УЗНАЮЩИХ РЕЦЕПТОР ИНТЕРЛЕЙКИН-2, ДЛЯ ПРЕДУПРЕЖДЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСАМИ СПИДа
JOHANRLILLEHAUG RNA splicing and SR protein phosphorylation under stress in acute myeloid leukemia (AML)